Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• Dendritic cells (DCs) are vital for antigen presentation and initiating immune responses.
• DC dysfunction in the tumor microenvironment (TME) can lead to cancer immune evasion.
• Understanding DC heterogeneity and dysfunction is key for effective cancer immunotherapy.

Purpose of the Study:

• To review factors within the TME that induce DC dysfunction.
• To identify signaling pathways and drugs involved in DC dysfunction.
• To summarize current clinical immunotherapies targeting DCs and explore future directions.

Main Methods:

• Literature review of factors affecting DC function in the TME.
• Analysis of signaling pathways implicated in DC dysfunction.
• Summary of clinical trials and outcomes for DC-targeting immunotherapies.

Main Results:

• Identified cytokines, hypoxia, tumor exosomes, metabolites, and co-inhibitory molecules as factors inducing DC dysfunction.
• Highlighted key signaling pathways and relevant drugs in clinical trials.
• Provided an overview of current DC-targeting immunotherapies with clinical outcomes.

Conclusions:

• Modulating DC function in the TME is critical for overcoming cancer immune evasion.
• Targeting DCs offers promising strategies for enhancing cancer immunotherapy efficacy.
• Future research should focus on novel DC-based immunotherapies with proven clinical benefits.